Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5990)
All Articles published online
|
Publishing Process of This Article
|
Apr 21, 2016 (publication date) through Jun 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ren J, Li G, Zhao W, Lin L, Ye T. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms. World J Gastroenterol 2016; 22(15): 3962-3968 [PMID: 27099439 DOI: 10.3748/wjg.v22.i15.3962] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i15/3962.htm |
| Number | Citing Articles |
| 1 |
Qing-qing Wang, Zi-xu Liu, Ping Wang, Bo-yuan Liu, Yu-peng Feng, Yu Zhang, Hai-bing He, Tian Yin, Xing Tang, Yan-jiao Wang, Jing-xin Gou. Intratumoral injection of norcantharidin liposome emulsion hybrid delivery system amplifies the cancer-fighting effects of oral sorafenib against hepatocellular carcinoma. Colloids and Surfaces B: Biointerfaces 2023; 232: 113599 doi: 10.1016/j.colsurfb.2023.113599
|
| 2 |
Mu-Su Pan, Jin Cao, Yue-Zu Fan. Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities. Chinese Medicine 2020; 15(1) doi: 10.1186/s13020-020-00338-6
|
| 3 |
Jiaxuan Xu, Xiaoqing Dong, David C. S. Huang, Peipei Xu, Quan Zhao, Bing Chen. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers 2023; 15(20): 4957 doi: 10.3390/cancers15204957
|
| 4 |
Chu-Liang Lin, Chien-Min Chen, Chia-Liang Lin, Chun-Wen Cheng, Chien-Hsing Lee, Yi-Hsien Hsieh. Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2017; 1864(10): 1867 doi: 10.1016/j.bbamcr.2017.07.015
|
| 5 |
Yao Chen, Ling Wang, Hao Liu, Fahuan Song, Caiyun Xu, Kai Zhang, Qing Chen, Shuang Wu, Yunqi Zhu, Ying Dong, Min Zhou, Hong Zhang, Mei Tian. PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice. Molecular Imaging and Biology 2018; 20(2): 309 doi: 10.1007/s11307-017-1108-4
|
| 6 |
Yun Zhou, Ke Li, Fan Li, Shuang Han, Yang Wang, Xueping Li, Yonghua Zhan. Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma. Journal of Nanomaterials 2019; 2019: 1 doi: 10.1155/2019/5274598
|
| 7 |
Eman H. Yousef, Nada F. Abo El-Magd, Amal M. El Gayar. Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway. Translational Research 2023; 260: 69 doi: 10.1016/j.trsl.2023.05.005
|
| 8 |
Mackenzie A. Scully, Dana E. Wilkins, Megan N. Dang, Elise C. Hoover, Sara B. Aboeleneen, Emily S. Day. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer. Molecular Pharmaceutics 2023; 20(8): 3895 doi: 10.1021/acs.molpharmaceut.3c00009
|
| 9 |
Zhe Ma, Bing Zhang, Yuqi Fan, Meng Wang, Dereje Kebebe, Jiawei Li, Zhidong Liu. Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases. Biomedicine & Pharmacotherapy 2019; 117: 109128 doi: 10.1016/j.biopha.2019.109128
|
| 10 |
Minchen Liu, Jue Tu, Yi Feng, Jiquan Zhang, Jing Wu. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma. Journal of Nanobiotechnology 2020; 18(1) doi: 10.1186/s12951-020-00677-4
|
| 11 |
Qian Liu, Henglai Sun, Xinyu Li, Huagang Sheng, Liqiao Zhu. Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin. Molecules 2022; 27(22): 7740 doi: 10.3390/molecules27227740
|
| 12 |
Miaodong Wang, Peichun Peng, Zeshan Chen, Xin Deng. Nanoparticle Delivery of Active Traditional Chinese Medicine Ingredients:
A New Strategy for the Treatment of Liver Cancer. Current Pharmaceutical Biotechnology 2023; 24(13): 1630 doi: 10.2174/1389201024666230313151316
|
| 13 |
Ming-Hua Xie, Min Ge, Jia-Bei Peng, Xiao-Rui Jiang, Ding-Sheng Wang, Li-Qiang Ji, Yin Ying, Zeng Wang. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin. Pharmaceutical Development and Technology 2019; 24(5): 623 doi: 10.1080/10837450.2018.1550788
|
| 14 |
Huapeng Zhang, Gongquan Li, Guanghui Chen, Yi Zhang, Jie Pan, Hongwei Tang, Jie Li, Wenzhi Guo, Shuijun Zhang. Targeting Mcl-1 inhibits survival and self-renewal of hepatocellular cancer stem-like cells. Clinics and Research in Hepatology and Gastroenterology 2019; 43(3): 292 doi: 10.1016/j.clinre.2018.11.004
|
| 15 |
Md. Rezaul Islam, Abdur Rauf, Shopnil Alash, Md Naeem Hossain Fakir, Gazi Kaifeara Thufa, Mahbuba Sharmin Sowa, Dattatreya Mukherjee, Harendra Kumar, Md Sadique Hussain, Abdullah S. M. Aljohani, Muhammad Imran, Waleed Al Abdulmonem, Rekha Thiruvengadam, Muthu Thiruvengadam. A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways. Medical Oncology 2024; 41(6) doi: 10.1007/s12032-024-02333-5
|
| 16 |
Bing-Tao Zhai, Jing Sun, Ya-Jun Shi, Xiao-Fei Zhang, Jun-Bo Zou, Jiang-Xue Cheng, Yu Fan, Dong-Yan Guo, Huan Tian. Review targeted drug delivery systems for norcantharidin in cancer therapy. Journal of Nanobiotechnology 2022; 20(1) doi: 10.1186/s12951-022-01703-3
|